title: Role of CHK2 in cancer development.
abstract: DNA repair pathways enable tumour cells to survive DNA damage induced by external agents such as therapeutic treatments. Signalling cascades involved in these pathways comprise the DNA-dependent protein kinase (DNA-PK), Ataxia-telangiectasia mutated (ATM), ATM and Rad3 related (ATR) and checkpoint kinases I and 2 (Chk1/Chk2), among others. ATM and ATR phosphorylate, respectively, Chk2 and Chk1, leading to activation of checkpoints. Chk2 acts as a signal distributor, dispersing checkpoint signal to downstream targets such as p53, Cdc25A, Cdc25C, BRCA1 and E2F1. A role of Chk2 as a candidate tumour suppressor has been suggested based on both mouse genetics and somatic tumour studies. We will discuss here the possible role of this kinase in human carcinogenesis and the possibility to use it as a target to increment DNA damage in cancer cells in response to DNA-damaging therapies.
authors.affiliation: Instituto de Investigaciones Biomédicas C.S.I.C./U.A.M., Madrid, Spain. Rperona@iib.es
authors.forename: Rosario
authors.initials: R
authors.lastname: Perona
authors.forename: Verónica
authors.initials: V
authors.lastname: Moncho-Amor
authors.forename: Rosario
authors.initials: R
authors.lastname: Machado-Pinilla
authors.forename: Cristóbal
authors.initials: C
authors.lastname: Belda-Iniesta
authors.forename: Isabel
authors.initials: I
authors.lastname: Sánchez Pérez
mesh_terms: D000818:Animals; D064447:Checkpoint Kinase 2; D004249:DNA Damage / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D009369:Neoplasms / Q000201:enzymology*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000502:physiology*
chemical_list: D004791:Enzyme Inhibitors; D064447:Checkpoint Kinase 2; C578634:CHEK2 protein, human; C578633:Chek2 protein, mouse; D017346:Protein Serine-Threonine Kinases
references.citation: J Med Genet. 2006 Jul;43(7):e34
references.pmid: 16816021
references.citation: Cancer Res. 2000 Apr 15;60(8):2108-12
references.pmid: 10786669
references.citation: J Natl Cancer Inst. 1996 Jul 17;88(14):956-65
references.pmid: 8667426
references.citation: Curr Opin Drug Discov Devel. 2007 Jul;10(4):473-86
references.pmid: 17659489
references.citation: Clin Cancer Res. 2003 Nov 1;9(14):5252-6
references.pmid: 14614006
references.citation: Mol Cancer Ther. 2007 Mar;6(3):935-44
references.pmid: 17363488
references.citation: Nature. 2000 Mar 9;404(6774):201-4
references.pmid: 10724175
references.citation: Trends Cell Biol. 2006 Jun;16(6):285-92
references.pmid: 16682204
references.citation: Science. 1999 Dec 24;286(5449):2528-31
references.pmid: 10617473
references.citation: Science. 1990 Nov 30;250(4985):1233-8
references.pmid: 1978757
references.citation: Nat Rev Genet. 2006 Jan;7(1):45-54
references.pmid: 16369571
references.citation: Mol Cancer Ther. 2004 Apr;3(4):513-9
references.pmid: 15078995
references.citation: Am J Hum Genet. 2004 Dec;75(6):1131-5
references.pmid: 15492928
references.citation: Clin Cancer Res. 2006 Dec 1;12(23):6967-72
references.pmid: 17145815
references.citation: J Neurooncol. 2005 Aug;74(1):93-5
references.pmid: 16078115
references.citation: Mol Cell Biol. 2004 Jan;24(2):708-18
references.pmid: 14701743
references.citation: Cancer Res. 2006 Feb 1;66(3):1401-8
references.pmid: 16452195
references.citation: Clin Transl Oncol. 2006 Sep;8(9):642-6
references.pmid: 17005466
references.citation: Cancer Res. 1988 Sep 15;48(18):5358-62
references.pmid: 3409256
references.citation: Annu Rev Genet. 2006;40:187-208
references.pmid: 16805666
references.citation: Cancer Res. 2006 Feb 1;66(3):1391-400
references.pmid: 16452194
references.citation: Mol Cell Biol. 2007 Feb;27(3):1007-16
references.pmid: 17101782
references.citation: J Biol Chem. 2000 Apr 7;275(14):10342-8
references.pmid: 10744722
references.citation: Oncogene. 2007 Dec 10;26(56):7816-24
references.pmid: 18066095
references.citation: Cancer Res. 2005 Jul 15;65(14):6017-21
references.pmid: 16024600
references.citation: Int J Colorectal Dis. 2008 Dec;23(12):1243-9
references.pmid: 18679694
references.citation: Genes Dev. 1999 Jan 15;13(2):152-7
references.pmid: 9925639
references.citation: Oncogene. 2001 Nov 8;20(51):7453-63
references.pmid: 11709716
references.citation: Nat Genet. 2002 May;31(1):55-9
references.pmid: 11967536
references.citation: Gynecol Oncol. 2006 Sep;102(3):429-31
references.pmid: 16828850
references.citation: Breast Cancer Res. 2002;4(3):R4
references.pmid: 12052256
references.citation: Breast Cancer Res Treat. 2004 Jan;83(1):91-3
references.pmid: 14997059
references.citation: Mol Cell. 2008 Jul 11;31(1):21-32
references.pmid: 18614044
references.citation: Nat Rev Cancer. 2007 Dec;7(12):925-36
references.pmid: 18004398
references.citation: J Biol Chem. 2000 Feb 25;275(8):5600-5
references.pmid: 10681541
references.citation: J Med Chem. 2005 Mar 24;48(6):1873-85
references.pmid: 15771432
references.citation: Cancer Res. 2003 Dec 1;63(23):8153-7
references.pmid: 14678969
references.citation: Biochem Soc Trans. 2001 Nov;29(Pt 6):655-61
references.pmid: 11709049
references.citation: Cancer Res. 2006 Dec 15;66(24):11576-9
references.pmid: 17178848